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Umbrella samplingThe interaction of PEGylated anti-hypertensive drugs, amlodipine, atenolol and lisinopril with lipid bilayermem-
brane dimyristoylphosphatidylcholine (DMPC) has been studied in nine different simulation systems consisting
of 128 lipidmolecules and appropriate number ofwatermolecules bymolecular dynamicsmethod and by utiliz-
ing GROMACS software. The inﬂuences of PEGylation on the mentioned drugs and the differences in application
of two types of spacer molecules on the performance of drugs and DMPC membrane have been evaluated and
mass density of the components in the simulation box,mean square displacement (MSD), electrostatic potential,
hydrogen bonding, radial distribution function (RDF), area per lipid, order parameter, and angle distribution of
the componentmolecules includingdrug, DMPC and PEGhas been investigated. Furthermore, umbrella sampling
analysis indicated that, PEGylation of the drugsmade amlodipine to behavemore hydrophilic, whereas in case of
lisinopril and atenolol, PEGylation made these drugs to behavemore hydrophobic. In almost all of the simulated
systems, PEGylation increased the diffusion coefﬁcient of the drugs.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In kidney and cardiovascular diseases hypertension is a risk factor
[1]. Hypertension is treated by regulating blood pressure and electrolyte
balance [1]. Amlodipine, atenolol, lisinopril and captopril are some
common drugs that are prescribed for high blood pressure treatment
[1–3]. The classiﬁcation of hypertension into mild, moderate and severe
requires speciﬁc treatment for each level of suffering from the disease
[4].
Amlodipine (shown in Fig. 1a) ((RS)-3-ethyl 5-methyl 2-[(2-
aminoethoxy) methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydro-
pyridine-3,5-dicarboxylate) is a dihydropyridine Ca2+ channel blocker
and is widely used as a hypertension treatment drug. Moreover,
amlodipine known as Norvasc is useful in cancer treatment and can be
synthesized by crystallization from organic solvents [5,6]. 1,4-
Dihydropyridine-based drug molecules such as amlodipine are used to
treat cardiovascular disorders [7,8].
Atenolol (shown in Fig. 1b) (2-(4-{2-hydroxy-3-[(propan-2-yl)
amino] propoxy} phenyl) acetamide) is a frequently used beta-blocker
in the treatment of hypertension and cardiovascular diseases due to
its anti-hypertensic and anti-arrhythmic characteristics [9–12].5875-4413, Iran. Tel.: +98 21Lisinopril (shown in Fig. 1c) ((2S)-1-[(2S)-6-amino-2-{[(1S)-1-
carboxy-3-phenylpropyl] amino}hexanoyl] pyrrolidine-2-carboxylic
acid), as an ACE (Angiotensin I-Converting Enzyme) inhibitor is widely
used in the treatment of hypertension [13–16]. Lisinopril is marketed
with the trade names of Zestril and Prinivil [17]. One of the beneﬁts of
using Lisinopril is the ability of the drug to maintain its properties,
when applied with other compounds such as nano carriers [18–20].
In drug delivery systems, themain goals are targeting and protecting
of the drug molecules. Nanomedicine has simpliﬁed the way to reach
the best drug designmechanism. Nanoparticles, dendrimers, liposomes
are applied as vehicles for safe targeting delivery of the drugs and are
considered as the novel areas for research. Poly(ethylene-glycol)
(PEG) (shown in Fig. 1d) is one of themost commonly used coatingma-
terials for nanoparticles [21,22], since PEG is soluble in both polar and
nonpolar solvents which is due to the presence of polar oxygen atom
and nonpolar (CH2)2 group in ethylene glycol. The procedure in which
the drug molecule conjugates to PEG is called PEGylation and the
PEGylated hydrophobic drug is protected from immune system of the
human body. Furthermore, the structure of PEG and its interactions
with the drug molecules in the physiological environment enhance
the circulation of blood [22]. Therefore, PEG and monomethoxy PEG
(mPEG) play a main role in polymer-based drug delivery systems [22].
A PEGylated prodrug consists of three molecules: drug, spacer and
PEG. An important point in conjugation of drug molecules with PEG is
the presence of functional groups (such as\\COOH,\\OH,\\SH and
Fig. 1. The structure of (a) amlodipine, (b) atenolol, (c) lisinopril, (d) PEG, (e) DMPC, (f) mPEG with amide spacer and (g) mPEG with ester spacer with their atom names referred in
the text.
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such as ester or amide which are formed between drug-spacer-PEG
are the determining factors in the stability of the prodrug [23–30]. The
characteristics gained by the drugs in conjugation with PEG have led the
food and drug administration (FDA) to approve their pharmaceutical ap-
plications [31]. On the other hand, side-reactions, drug functionalities and
availability of the reactive groups must be taken into account to reduce
the disadvantages of this process. PEGylation has been applied to nano
drugs which are prescribed as anti-tumor, antiviral, anti-inﬂammatory,
and anti-microbial [31]. In the case of nano drugs, not only the PEGylation
sites and PEG chain length are important [32], but the interactions be-
tween the drug molecules (PEGylated or not) and lipid bilayers are also
determining factors which should be considered to understand the be-
havior of drugmoleculeswhen they come into contactwith the phospho-
lipid cell membranes. The phosphatidycholines, which are the chain
branchings in phospholipid molecular structure, are the most abundant
components in the plasma membrane of vascular systems [3]. The drug
interactions with phospholipid DMPC (dimyristoylphosphatidylcholine)
membrane (Fig. 1e) have been investigated by many researchers
[33–53]. Therefore, in thiswork the drugs amlodipine, lisinopril and aten-
olol have been PEGylated and then their interaction with DMPC mem-
brane has been studied to elucidate the drug and membrane behavior.
Molecular dynamics (MD) simulations as an effective tool have been
utilized to achieve the purpose of this research. The almost entirely un-
knownmechanism of altering drug behavior after PEGylation and its in-
teractions with DMPC membrane is one of the fundamental reasons to
use molecular simulation to obtain interpretable results which are not
attainable by experimental procedures. MD simulation is a reliablemethod which has been applied to study the interactions of drug mole-
cules and model phospholipid membranes [49–55].
In this study, we focused on the role of PEGylation in hydrophilic
drug transport through the lipid bilayer membrane. The effect of
PEGylation on changing and interfering with the drugs' functionality
and also using a membrane with a receptor (as used in [56]) are impor-
tant topics for our future studies; therefore, the aims of this study are
outlined as follows:
1) Comparing the drug diffusion into the DMPC membrane in both or-
dinary and PEGylated forms.
2) Studying the behaviors of three types of anti-hypertensive drugs
(amlodipine, atenolol, and lisinopril) with three functionalities
such as calcium channel blockers, beta-blockers and ACE inhibitors.
3) Evaluating the orientation, location and agglomeration of the drug
molecules in the studied system.
4) Considering the membrane perturbation and conﬁguration in the
presence of different types of drug molecules.
5) Determining the inﬂuence of different types of spacers on the
PEGylated drug behavior.
2. Simulation methods
Nine different molecular dynamics simulations in the simulation
boxes of 6 ∗ 6 ∗ 10 nm were performed by using GROMACS (Groningen
machine for chemical simulations) 4.5 package [57–61]. The ﬁrst three
simulations were done on three types of the anti-hypertensive drugs
(amlodipine, atenolol and lisinopril), PEGylated with tetraethylene
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shown in Fig. 1f) in the presence of appropriate number of water mole-
cules and a well-equilibrated DMPC lipid bilayer membrane with 64
lipidmolecules per leaﬂet [62,63]. The next three simulationswere per-
formed containing the drug molecules in their ordinary form (not
PEGylated), and the last three simulations were done on the drugs
PEGylated by ester form spacers (as shown in Fig. 1g). The components
and their amounts in each simulation system are presented in Table 1;
also, the schematic presentations of three of the simulation systems,
as examples, are provided in Fig. 2 (and for other systems, the schematic
presentations are given in the supplementary data as Figs. S1 to S6).
After equilibrating the bilayer membrane for a 20 ns MD simulation,
four drug molecules were inserted in the simulation box (all in the sol-
vent bulk and on one side of the lipid bilayer membrane). The SPC (sin-
gle point charge) approximation for water molecules was then utilized
to solvate the whole system. The united atom model, for reducing the
computation time, was used for the DMPC and the drug molecules
[64]. The reliable GROMOS force ﬁeld [65–69], modiﬁed by Berger [70]
was applied. The initial structures of the drug molecules were obtained
by PRODRG server [71]. Moreover, the atomic charges prepared by
PRODRG were modiﬁed by Hartree–Fock quantummechanical calcula-
tion, using Spartan software (Wavefunction, Irvine, CA) [67]. After neu-
tralizing the simulation systems with the appropriate number of ions
(Na and Cl), each system was energy minimized and equilibrated in
NVT (for 10 ns) and NPT (for 10 ns) ensembles. After setting the tem-
perature of the simulation systems at 310 K (to have a liquid crystalline
structure of DMPC) by Nose–Hoover [39] thermostat (with a coupling
time constant of 0.5 ps) and the pressure at 1 bar by Parrinello–Rahman
barostat [72] (with a coupling time constant of 2 ps), the 100 ns produc-
tion runwas set by using the following simulation conditions: the linear
constraint solver (LINCS) algorithm [73] was applied to constraint all
bonds. The leap frog algorithm was utilized for integration with a time
step of 2 fs. Periodic boundary condition was used in x, y and z direc-
tions. A Lennard–Jones cutoff radius of 1 nm, a particle-mesh Ewald
(PME) sum [74] with a 1 nm cutoff, fourth PME order, 0.12 nm fast-
Fourier grid spacing and 10−5 tolerance were also applied and every
10 fs the neighbor list was updated.
Also, potential of mean force (PMF) has been calculated using um-
brella sampling with a force bias perpendicular to the membrane to
investigate the partitioning of the drugs and their permeation into theTable 1
The components of the simulation systems.
Simulation
system name
Components
Amlodipine DMPC lipid bilayer (128 lipid molecules) + 4 amlodipine
molecules + water (about 3300 molecules) + 4 Cl ions
Atenolol DMPC lipid bilayer (128 lipid molecules) + 4 atenolol
molecules + water (about 3400 molecules) + 4 Cl ions
Lisinopril DMPC lipid bilayer (128 lipid molecules) + 4 lisinopril
molecules + water (about 3300 molecules)
Amidamlodipine DMPC lipid bilayer (128 lipid molecules) + 4 amlodipine
molecules, PEGylated by amide spacers + water (about 3300
molecules)
Amidatenolol DMPC lipid bilayer (128 lipid molecules) + 4 atenolol
molecules, PEGylated by amide spacers + water (about 3300
molecules) + 4 Cl ions
Amidlisinopril DMPC lipid bilayer (128 lipid molecules) + 4 lisinopril
molecules, PEGylated by amide spacers + water (about 3300
molecules) + 4 Na ions
Esteramlodipine DMPC lipid bilayer (128 lipid molecules) + 4 amlodipine
molecules, PEGylated by ester spacers + water (about 3300
molecules)
Esteratenolol DMPC lipid bilayer (128 lipid molecules) + 4 atenolol
molecules, PEGylated by ester spacers + water (about 3300
molecules) + 4 Cl ions
Esterlisinopril DMPC lipid bilayer (128 lipid molecules) + 4 lisinopril
molecules, PEGylated by ester spacers + water (about 3300
molecules) + 4 Na ionsmembrane by considering the obtained free energy proﬁles. The drug
molecules (PEGylated and non-PEGylated) have been pulled from
their ﬁrst location (bulk water) into the lipid bilayer along the z-
direction using a pulling rate of 0.01 nm/ps and a force constant of
1000 kJ/(mol·nm2) for a harmonic spring. For each simulation system
(three systemswere used for the PEGylated forms of the drugs, and an-
other three systems for the non-PEGylated forms), 15 frameswith a dis-
tance changes of about 0.2 nm between the center of mass of the drug
and the lipid bilayer have been extracted. After constraining the z dis-
tance between the center of mass of the drug and the bilayer using a bi-
asing harmonic potential, each frame (window) has been equilibrated
for 5 ns and a production run of 15 ns has been applied. The weighted
histogram analysis method (WHAM) has been used to calculate the po-
tential of mean force (PMF) across a monolayer of the membrane [49].
Due to the bilayer structural symmetry, the obtained PMF proﬁle for a
monolayer has been applied to the othermonolayer of theDMPC bilayer
membrane. Furthermore, the bootstrap technique has been used to ap-
prove the accuracy of the obtained results. It should be noted that, the
two spacers used in the drug–PEG conjugation did not indicate a signif-
icant difference on the energy proﬁles; therefore, the simulation results,
presented in Fig. 8 are only for the amide bonded spacer molecule.3. Results and discussion
3.1. Mass densities
Mass density analysis has been performed to evaluate the behav-
ior of the simulated systems in the presence of the different types of
the drug molecules. Fig. 3 illustrates the mass density distribution of
drugs amlodipine, atenolol, lisinopril in the ordinary and PEGylated
forms, DMPC lipid bilayer membrane and solvent molecules. The
asymmetry in the membrane localization of the drugs is due to the
drug insertion from one side of the membrane. Fig. 3a indicates
that, the PEGylation caused amlodipine molecules to be located in
the solvent bulk and at a distance from the lipid bilayer membrane,
whereas in the ordinary form there is a tendency of the drugs to
penetrate into the lipid bilayer and locate itself somewhere between
the hydrophobic and hydrophilic region of the membrane. Moreover,
the sharp curve obtained from the simulation of amlodipine mole-
cules PEGylated by the spacers containing ester and amide groups
can be due to the accumulation of the drug molecules (as shown
in Fig. 2). This accumulation in some cases can be useful for drug ef-
fects on the target, as well as for PEGylated mitosome, which accu-
mulates more in tumor tissues by an enhanced permeability [5].
The mentioned behavior for the PEGylated atenolol is not as sharp
as amlodipine. However, a smooth shift in the density proﬁle of the
PEGylated atenolols to the hydrophobic region is seen in Fig. 3b. As
shown in Fig. 3c, PEGylation's inﬂuence on the density distribution
of lisinopril molecules indicates a slight increased tendency for the
PEGylated drugs to locate themselves closer to the hydrophobic re-
gions of the lipid bilayer membrane.
Fig. 3d indicates that, the PEG molecules have their hydrophilic be-
havior except in the system containing PEGylated atenolol with an
amide bond. However, (even very small) the density of PEG in the hy-
drophilic region conﬁrms the amphiphilic nature of PEG. In Fig. 3e the
density distributions of lipid and water molecules are presented.
It can be deduced that, PEGylation has the highest effect on the
amlodipine molecules location in the membrane, compared with the
other types of the simulated drugs in this work. However, this is not a
desired effect, since it prevents the diffusion of the drug molecules
into the lipid bilayer membrane. Furthermore, the type of spacer used
in the PEGylated drugs has a negligible effect on the drug behavior.
Fig. 2. The drug molecules' shapes after equilibration and the snapshots of the simulation systems containing amlodipine (PEGylated and ordinary forms).
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Mean square displacement (MSD) calculation can be helpful in eval-
uating the drug's movement in the simulated systems. Diffusion coefﬁ-
cient also can be determined from MSD calculation using Einstein's
equation [49]:
D ¼ limt→∞ 14
d
dt
r t þ t0ð Þ−r t0ð Þ½ 2
D E
t0
ð1Þ
where r(t0) and r(t+ t0) are the position vectors of the simulated mol-
ecules at time t0 and t + t0 respectively, and the angle brackets show
their mean square deviation at time t0. Table 2 represents the diffusion
coefﬁcients of the drug, lipid and PEG molecules in different simulation
systems. The results are obtained from the slope of the curves that are
shown in supplementary data as Figs. S7–S13 at the time interval of
104–9 × 104 ps, where the least ﬂuctuations are observed in the MSD
curves. The highest values of the diffusion coefﬁcients correspond to
the drugs PEGylated by the ester spacer. For the systems containing
lisinopril, a meaningful increase in diffusion coefﬁcient can be seen by
an ester PEGylation in comparison with the ordinary and PEGylated
forms (by a spacer containing amide group). On the other hand, the or-
dinary form of atenolol represents lower values of the diffusion coefﬁ-
cient in comparison with the PEGylated (ester and amide) forms. In
both systems, containing lisinopril and atenolol, the PEGylated forms
of the drugs represents more movements compared with the ordinary
form; whereas, the ordinary form of amlodipine has the diffusion coef-
ﬁcient and meanmovement values, which are in between the values of
the two forms of PEGylated drugs (shown in Figs. S7–S9). Fig. S10 illus-
trates the MSD curves of lipid molecules in the systems containing dif-
ferent forms of amlodipine. It can be deduced from this ﬁgure that, the
differences between the lipid movements in the simulated systems
are negligible Also, Figs. S11 and S12 represent the same behavior for
the lipidmolecules in the presence of atenolol and lisinopril. The behav-
ior of PEG molecules are also similar to the drug molecules, which
means the higher values of diffusion coefﬁcients and molecular move-
ments are obtained for the systems containing PEGylated drugs byester bonded spacer compared with the ordinary and amide bonded
systems (see Fig. S13).
As a result, almost in all of the simulated systems, the PEGylation in-
creases the diffusion coefﬁcient and the ester bonded spacers indicate a
much more effect on the molecular movements.
3.3. Electrostatic potential
Drug insertion into the system containing lipid bilayer membrane
andwatermolecules can change the electrostatic potential due to orien-
tation of water dipoles and lipid head group dipoles at the water–
membrane interface; moreover, in some of the simulated systems the
ions added to neutralize the whole system may cause an electrostatic
potential. Poisson equation relates the charge density distribution
along Z-axis ρ(z) to the electrostatic potential ψ(z) by [49]:
d2Ψ zð Þ
dz2
¼−ρ zð Þ
ε0
ð2Þ
where ε0 is the vacuum permittivity (the relative permittivity is set to 1
in atomistic simulations). Integrating Eq. (2) twice and utilizing the
boundary conditions lead us to evaluate the electrostatic potential.
The charge distribution is calculated from the partial atom charges set
in the force ﬁeld. The total electrostatic potentials for the simulation
systems are illustrated in Fig. 4.
The electrostatic potentials as evaluated for all of the simulation sys-
tems containing the anti-hypertensive drugmolecules show an increase
comparedwith the systemwithout the drugmolecules (as shown inour
previous studies [49–51]). It can be seen in Fig. 4 that, the highest and
the lowest values for the electrostatic potential respectively have oc-
curred in the systems consisting of amlodipine and lisinopril molecules
(in their ordinary forms, without PEGylation). Whereas, PEGylation
(with both ester and amide spacers) increases the electrostatic potential
in the systems containing atenolol and lisinopril molecules.
According to Fig. 4, applying both types of spacer molecules has the
same effect on increasing (for lisinopril and atenolol) and on decreasing
(for amlodipine) the electrostatic potential compared with the values
obtained in the systems containing the ordinary forms of thementioned
Fig. 3.Mass densities of (a) amlodipine, (b) atenolol, (c) lisinopril, (d) PEG, and (e) water (down) and lipid (up) molecules in different systems.
Table 2
Diffusion coefﬁcients (×107 cm2 s−1) of different components in different systems.
Simulation system Drug DMPC PEG
Amlodipine 3.67 0.43 –
Atenolol 0.81 0.84 –
Lisinopril 0.58 0.54 –
Amidamlodipine 1.38 0.43 2.58
Amidatenolol 1.41 0.36 1.90
Amidlisinopril 0.93 0.44 1.84
Esteramlodipine 3.91 0.43 2.58
Esteratenolol 2.64 0.89 2.28
Esterlisinopril 1.43 0.59 2.20
1691A. Yousefpour et al. / Biochimica et Biophysica Acta 1848 (2015) 1687–1698drugs; also, the amount of the electrostatic potential differences be-
tween PEGylated and ordinary forms is independent of the spacer
type (amide or ester bonded). The occurred changes in electrostatic
potential can be due to the ﬂexibility of PEGylated drugs in altering
the orientation of the lipid chains [30].
It can be concluded from this analysis that, the insertion of the drug
molecules in the studied simulation systems increases the electrostatic
potential, but this increase varies for different types of anti-
hypertensive drugs (both in ordinary and PEGylated forms). This in-
crease can be compared with the electrostatic interaction blockings
caused by PEGylation, as reported in the other studies [27]. The mean-
ingful difference between the electrostatic potential in the presence of
Fig. 4. Electrostatic potential of the simulated systems.
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due to the Cl atom in the structure of amlodipine; therefore, PEGylation
of this drug reduces the Cl effect on increasing the electrostatic poten-
tial, since PEGylation changes the orientation of the lipid head groups
against the drug molecules.
3.4. Hydrogen bonding
Hydrogen bonding strongly affects the distances between electron
donor hydrogen and electron acceptor atoms (such as oxygen), and
also the acceptor–donor bond angle, where hydrogen bonds are formed
between the functional groups OH and NH. The bond distance of less
than 2.5 Å and simultaneously the bond angle of acceptor–hydrogen-
donor more than 90° are considered as the evidences of hydrogen
bond formation [49].
Table 3 illustrates the average number of hydrogen bonds formed
between drug–drug, drug–DMPC, drug–water, drug–PEG, and DMPC–
water in different simulation systems. The highest number of hydrogen
bonds is formed between drug–drug for the system containing
PEGylated atenolols by ester bonded spacer, and the strong hydrogen
bonds between drug–drug cause their agglomeration. Moreover, the
lowest numbers of hydrogen bonds in this analysis correspond to the
systems consisting of atenolol and amlodipine in their ordinary form.
As can be seen in Fig. 3a and b, the ﬂat mass density distribution for
the mentioned systems conﬁrms this point. On the other hand, almost
the same mass density distribution for the three simulation systems
containing lisinopril molecules, as shown in Fig. 3c, is consistent with
the number of hydrogen bonds formed between these molecules. It
can be deduced from the results in Table 3 that, PEGylation of theTable 3
Average number of hydrogen bonds between the components in the simulation systems
per time frame.
System Drug and
drug
Drug and
DMPC
Drug and
water
Drug and
PEG
DMPC and
water
Amlodipine 0.008 5.662 17.251 – 801.116
Atenolol 0 7.279 6.157 – 794.84
Lisinopril 0.062 2.566 58.38 – 726.35
Amidamlodipine 0.348 0.015 29.089 0.209 801.421
Amidatenolol 0.49 2.93 39.91 10.28 808.237
Amidlisinopril 0.072 2.581 35.84 0.013 725.10
Esteramlodipine 0.093 0.025 21.794 0.172 800.266
Esteratenolol 0.870 1.628 7.420 0.222 800.072
Esterlisinopril 0.065 2.573 43.72 0.008 725.033three simulated drugs leads effectively to drug–drug hydrogen bonds
formation, comparedwith their ordinary forms, and this can be attribut-
ed to the presence of more donor groups in the PEGylated systems.
Therefore, formation of higher number of hydrogen bonds in the
PEGylated drugs acts as a strong driving force for drug diffusion. As
can be seen in Table 3, the systems containing PEGylated atenolols
(both with ester and amide spacers) have the highest number of
drug–drug hydrogen bonds which can be due to the presence of more
donor groups in these systems; whereas, for the system containing
the ordinary form of atenolol, the number of hydrogen bonds is lower.
Therefore, the steric altering of the drug molecule (atenolol) causes
more hydrogen bond formation.
The systems containing ordinary forms of atenolol or amlodipine
molecules have lower number of drug–drug hydrogen bonds andhigher
number of drug–DMPC hydrogen bonds, but the number of hydrogen
bonds is the lowest for the systems containing PEGylated amlodipines
(both ester and amide). The higher number of drug–DMPC hydrogen
bonds brings the drug molecules closer to the DMPC membrane.
The highest number of hydrogen bonds is formed between drug–
PEG in the systems containing the PEGylated forms of atenolols, in
both ester and amide forms, but for the amide form it is higher than
the ester form. Hydrogen bond formation changes the PEGylated
drugs structure from linear to a semi-spherical structure. This is seen
in the snapshots of the drug molecules which are taken after the pro-
duction run (Fig. 2).
The system containing lisinopril molecules has the highest number
of hydrogen bonds between drug–water molecules; formation of
these bonds decreases the diffusion coefﬁcient of the drug and retards
the drug movements in the simulation system (this can be seen in
Table 2).
The number of hydrogen bonding between water–DMPC molecules
is in the lowest for the systems containing lisinopril (PEGylated or not).
This is due to the fact that, while in this system the lisinopril molecules
ﬁnd a pathway tomove between thewatermolecules toward theDMPC
lipid bilayermembrane, in the systems containing amlodipine and aten-
olol molecules, the water molecules are pushed toward the bilayer and
as a result they will be located closer to the membrane These phenom-
ena cause formation of lower (for the systems containing lisinopril) and
higher (for the systems containing atenolol or amlodipine) number of
hydrogen bonds between water–DMPC molecules compared with the
system in the absence of the drug molecules [49].
It can be concluded from this analysis that, PEGylation has almost
the same inﬂuence on amlodipine and atenolol; while, PEGylated
lisinopril shows more tendency to behave as a hydrophobic drug.
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Fig. 5 illustrates the radial distribution function (RDF) of the simulat-
ed drugs. By this analysis, the probability of watermolecules around the
drug molecules, and their hydration can be evaluated. The ﬁrst maxi-
mum point in each curve determines the ﬁrst layer of water molecules
around the drugs. This ﬁgure indicates that, the drug afﬁnity to accept
water molecules for the ordinary forms of amlodipine and atenolol is
less than that of their PEGylated forms. On the other hand, an inverse
behavior is observed for lisinopril molecules, which indicates that, the
RDF for ordinary form is higher than its PEGylated form. It can be con-
cluded from Fig. 5 that, PEGylation affects the RDF curves for theFig. 5. Radial distribution function for several simulation systems.systems containing amlodipine or atenolol muchmore than the system
containing lisinopril. These results are consistent with the results ob-
tained for hydrogen bond formation (see Table 3). The higher tendency
of the drugs to be surrounded by water molecules is consistent with
their strong afﬁnity to form hydrogen bonds with the water molecules.
Hydration number also can be calculated by integrating Eq. (4) up to
(r) the ﬁrst minimum in the RDF curves [49]:
N ¼
Z r
r¼0
N rð Þ ¼
Z r
r¼0
4πr2ρg rð Þdr ð3Þ
where N(r) is the number of water molecules in the ﬁrst shell with a
thickness of dr at a distance r from the center of mass of the drugmole-
cule and ρ is the number density of water molecules. The hydration
numbers for the studied systems are presented in Table 4.
For all of the simulated systems (in Fig. 5), the ﬁrst minimum, in the
RDF curves, occurs at a distance of 0.218 nm; therefore, the probability
of the water molecules surrounding the drug molecules (both in ordi-
nary and PEGylated forms) are almost the same. The calculated hydra-
tion numbers given in Table 4 indicate that, the maximum and the
minimum probabilities of water molecules surrounding the drug mole-
cules are respectively for the systems containing ordinary lisinopril and
PEGylated atenolol by an amide bonded spacer. The differences be-
tween the number of hydrogen bonds and the RDF for the system con-
taining PEGylated atenolol by amide bonded spacer are due to the
stronger afﬁnity of the PEGylated drug to form hydrogen bonds even
with a low number of water molecules. Therefore, a direct relationship
between hydration number and number of hydrogen bonds cannot be
always true.
3.6. Area per lipid
By multiplying the two dimensions (xy) of the simulation box and
dividing the result by the number of lipid molecules in one leaﬂet of
the lipid bilayer membrane (64 molecules in this study), an important
parameter called area per lipid can be evaluated. The lipid membrane
equilibration and its distance from the phase transition condition can
be studied by area per lipid analysis. The average area per lipid and
the time evolution of the area per lipid (DMPC) for the simulated sys-
tems are presented in Fig. 6 (the time evolutions of the area per lipid
for all of the simulation systems are provided separately in the Supple-
mentary data, Figs. S14–S22). It is evident that, all the systems remained
in the liquid crystalline phase [49].
The maximum area per lipid corresponds to the system containing
amlodipine molecules in their ordinary form. For all of the simulated
systems a meaningful reduction has been obtained in comparison
with a system in the absence of the drugmolecules [49]. These calculat-
ed results show that, the lipid molecules have tendency to approach
each other. As can be seen in Fig. 6, the system containing the PEGylated
lisinoprils (with a spacer containing amide bond), has the least value of
area per lipid.
Insertion of lisinopril molecules (PEGylated or not) in the simulation
systems has the highest inﬂuence on the lipid (DMPC) chains to changeTable 4
Average hydration numbers of the simulated drugs.
System Hydration number
Amlodipine 0.0981
Atenolol 0.0516
Lisinopril 0.2330
Amidamlodipine 0.1840
Amidatenolol 0.0492
Amidlisinopril 0.1940
Esteramlodipine 0.1340
Esteratenolol 0.0599
Esterlisinopril 0.1880
Fig. 6. The area per lipid and the time evolution of the area per lipid for the simulated systems.
Fig. 7. The order parameters of chain 1 (a) and chain 2 (b) of the lipid.
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per lipid (as shown in Fig. 6). One of the obvious reasons of this phe-
nomenon is the low number of hydrogen bonds formed between
DMPC–water molecules. More interactions between the lipid head
groups, due to the lack of water molecules in their vicinity, bring the
DMPCmolecules closer to each other andwouldmake a compact struc-
ture for the DMPC molecules compared with in the other simulation
systems.
3.7. Order parameter
By order parameter analysis, themovements for lipid (DMPC) chains
and the ﬂuctuations that occur in a very short period of time can be
taken into account. Also, lipid chain disorders in the membrane can be
evaluated by this analysis. The order parameter is expressed as [49]:
S ¼ 3 cos
2θ−1
2
 
ð4Þ
where θ is the angle between themolecular vector and the vectorwhich
is parallel to the bilayer normal (z). The angle brackets in this equation
correspond to the time averaged value.
Fig. 7 illustrates the order parameter data for both chains 1 (Fig. 7a)
and 2 (Fig. 7b) of DMPC lipid bilayer membrane. As can be seen in this
ﬁgure, the highest and the lowest values of the disorders are respective-
ly for the systems containing amide form of the PEGylated lisinoprils
and the ordinary form of amlodipines. The results are consistent with
those of Fig. 6 for the area per lipid in different simulation systems.
Themaximumvariation in the lipid chain locations occurs in the system
containing amide form of the PEGylated lisinopril; therefore, the maxi-
mum value of order parameter should be expected for this simulation
system. These results indicate the inﬂuences of PEGylation, in amide
form of lisinopril molecules, on the lipid chain disorders.
Table 6
Drug, lipid and PEG molecules orientation, average angle (AA) and most probable angle
(MPA).
Simulation system Component
Drug Lipid PEG
AA MPA AA MPA AA MPA
Amidamlodipine 90.5 91.4 26.2 37.3 129.1 156.3
Amidatenolol 95.8 61.4 23.2 19.7 75.6 62.2
Amidlisinopril 48.0 161.5 85.7 84.4 101.3 164.3
Amlodipine 83.2 84.3 31.5 31.6 – –
Atenolol 92.0 95.1 23.5 24.2 – –
Lisinopril 81.1 102.4 93.4 94.3 – –
Esteramlodipine 90.0 91.5 30.8 37.2 105.4 95.7
Esteratenolol 59.0 20.1 28.4 23.5 87.9 120.3
Esterlisinopril 61.7 21.3 88.3 94.3 89.5 143.2
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To evaluate the system behavior during the simulation time, the
angle distribution analysis has been performed. The drug and lipid
chain orientations, as the important parameters in the molecular simu-
lation, can be deﬁned by appropriate vectors for both drug and lipid
molecules. In this research, the vectors formed by the two speciﬁed
atoms in the drug and lipid molecules are considered as represented
in Fig. 1 and in Table 5.
The angle between the mentioned vectors and the normal vector of
the lipid bilayer membrane, which is parallel to the z-axis, has been an-
alyzed by GROMACS angle distribution calculators during the 100 ns
time of MD simulation. The zero angle is for the direction out of the
(or perpendicular to the) lipid bilayer membrane surface. Table 6
shows the average and the highest probable values (in degrees) for
the calculated angles (for the drug molecules). The data obtained for
the lipid chains are for the angles between the normal vector of the
bilayer and the vector formed by the atoms P and N as shown in Fig. 1.
Figs. S23, S24 and S25 (in the supplementary data) show the angle
distribution during the 100 ns production run. The angle distribution
of PEG molecules in the simulation systems is provided as the Supple-
mentary data (Figs. S26–S28).
As is shown in the mentioned ﬁgures and tables, amlodipine mole-
cules (PEGylated or ordinary) prefer to be oriented perpendicular to
the lipid chains. Almost the same average angles for the amlodipine
molecules in the PEGylated and in the ordinary forms justify the fact
that, PEGylation does not have signiﬁcant effect on the angle distribu-
tion. The highest effect of PEGylation on the angle distribution on the
amlodipine molecules appears as a 7° decrease in the orientation of
the drug molecules which makes the angle more compatible for the
drug to diffuse into the lipid bilayer membrane. The maximum effect
of PEGylation on the angle distribution corresponds to the system con-
taining atenolol molecule PEGylated by an ester spacer. Atenolol mole-
cules in their ordinary form prefer to be oriented perpendicular to the
lipid bilayer membrane, but the PEGylation reduces the angle between
the drug vector and the lipid bilayer normal vector (the differences
are about 30° and 70° for the PEGylated drugs respectively for amide
and ester spacers). The drug molecules diffuse into the lipid bilayer
membrane and the drug–drug interactions make changes in the drug
orientation to be located in an optimized orientation in respect to the
lipid chains. PEGylation by both types of ester and amide spacers result-
ed in an angle change of about 60° for the systems containing lisinopril
molecules. These signiﬁcant differences in angle distribution justify the
importance of PEGylation in making the drug molecules to achieve an
optimized orientation. The other fact deduced from the angle distribu-
tion analysis of lisinopril molecules is the negligible effect of the spacer
type (amide or ester) on the drug orientation where both of the spacers
resulted in almost the same change in the drug orientations (but in dif-
ferent directions in respect to the normal vector of the lipid bilayer).
The PEG angle orientations are reported in Table 6 and also are pro-
vided as the supplementary data, which show how the long chains of
PEG are oriented during the simulation time. The sharp PEG angle distri-
bution curves for the PEGylation by amide spacers (for the three studied
drugs), are compared with those of ester spacers, which demonstrate
higher stability for the PEG molecules orientation in the PEGylation by
amide spacer. Furthermore, whenever the PEGylated drug orientationTable 5
Speciﬁed atoms in different systems to form vectors.
Simulation system Drug vector (atom 1–atom 2) PEG vector (atom 1–atom 2)
Amide spacer Ester spacer
Amlodipine CLAG-NBA NBZ-CBU CBC-CBU
Atenolol NAJ-CAP NBI-CBO CBL-CBP
Lisinopril NAU-CAC CBV-NCA CBV-OBJin respect to the membrane is studied in a simulation system, the PEG
stability should also be taken into account.
As can be seen in Figs. S23(b), S24(b), S25(b) and in Table 6, a differ-
ence of about 23° to 30° occurs in the lipid chains to become parallel to
the normal vector of the lipid bilayermembrane, in all of the simulation
systems, except in the systems containing lisinopril (PEGylated or not)
molecules. These changes in the lipid chain orientations in the presence
of lisinopril molecules are consistent with the results obtained in the
order parameter and area per lipid analyses in this study. It is clear
that, lisinopril (both in PEGylated and ordinary forms) insertion in the
simulation systems has a considerable effect on the lipid chain orienta-
tions, compared with the other two types of simulated drugs (atenolol
and amlodipine). The different effects of PEGylation on the drugs are
consistentwith the results presented by Yu et al. [75], where PEGylation
of lysozyme altered the preferred orientation of lysozyme at the silica
surface.
The negligible effect of PEGylation on the orientation of the
amlodipine molecules, the same effects on the angle distribution by
both of the spacers and changing the directions of atenolol and lisinopril
molecules toward the bilayer membrane, are themost import results of
this analysis.
3.9. Free energy analysis
The obtained free energy proﬁles, by integrating themean force im-
posed on the z-direction, for amlodipine, atenolol and lisinopril
(PEGylated and non-PEGylated) are presented in Fig. 8. As can be seen
in Fig. 8, the maximum point of the proﬁles in the hydrophobic region
shows the hydrophilic behavior of the simulated drugs, but as it is obvi-
ous in this ﬁgure, the effect of PEGylation on the drugs is different in the
simulated systems. For atenolol and lisinopril, the meaningful decrease
at themaximumpoint of these proﬁles veriﬁes that, the lipophilic effect
of PEG on the drugs changes their behavior and facilitates the diffusion
into the bilayer membrane. On the other hand, amlodipine shows a
higher hydrophilic behavior after PEGylation which is due to the domi-
nant hydrophilic effect of the PEG as an amphiphilic molecule. The re-
sults of free energy calculations for the simulated drugs are consistent
with the mass density, hydrogen bonding, RDf obtained in this work.
From the results presented in Fig. 8, it can be concluded that, PEGylation
reduces the energy barrier against the penetration of the drugs into the
lipid bilayer for lisinopril and atenolol, but in contrast for amlodipine, an
undesired increase in the energy barrier is observed after PEGylation.
4. Conclusion
Three types of anti-hypertensive drugs, amlodipine, atenolol and
lisinopril, were studied in their ordinary and PEGylated forms (by two
types of amide and ester bonded molecules). All of the simulations
were performed in the presence of DMPC and appropriate number of
water molecules. The behavior of the drug molecules and the lipid
Fig. 8. Free energy proﬁles of the simulated drugs across the DMPC lipid bilayer membrane.
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density analysis shows that while the ordinary form of amlodipinemol-
ecules shows slight tendencies to diffuse into the lipid bilayer mem-
brane, the PEGylated forms of the drug (both with ester and amide
spacers) indicate the hydrophilic behavior. Moreover, the inﬂuence of
drug PEGylation on the location of lisinopril molecules appears as a
shift toward the lipid bilayer membrane, and the highest effect appears
for the system containing amlodipine molecules. The sharp curve ob-
tained from the mass density analysis of the systems containing
PEGylated amlodipine corresponds to accumulation of the drugs. From
the MSD analysis, it is concluded that, the ester form spacer has the
highest effect on the drug movement for all the simulated drugs. On
the other hand, the presence of the drug molecules increases the elec-
trostatic potential of systems (for all of the simulated systemswhich in-
clude water, DMPC and drugs) compared with the absence of the drug
molecules (only DMPC andwater). This increase in the electrostatic po-
tential does not depend on the type of the used spacer molecule. One of
the interesting results obtained in this analysis is that, the PEGylation
reduces the electrostatic potential by the insertion of amlodipine mole-
cules in the simulation systems. The results indicate that, the drug char-
acteristics can inﬂuence the electrostatic potential and the PEGylation
decreases this inﬂuence. The other structural effect on the results is
due to the hydrogen bond formation, where the PEGylated atenolols
have the highest number of drug–drug hydrogen bonds due to their
higher number of electron donor and acceptor atoms. Furthermore,
the steric effect of the drug molecules, results in formation of higher
number of hydrogen bonds. An interesting effect of hydrogen bonding
is seen in the PEGylated atenolol molecules, where the higher number
of drug–PEG hydrogen bonds causes the drugmolecule to form a spher-
ical structure. The low value of diffusion coefﬁcient resulted for the sys-
tem containing lisinopril molecules is consistent with the number of
hydrogen bonds between the drug–water molecules that hinder the
drug molecules movements. The analysis of the order parameter and
area per lipid shows that, lisinoprilmolecules have thehighest inﬂuence
on the lipid chain deformation. The results obtained for angle distribu-
tion analysis indicate the presence of an extreme perturbation in the
lipid orientations, in the systems containing the lisinopril molecules
(PEGylated or not).
The main results of this study can be summarized as follows:
1. PEGylation increases the tendency of lisinopril and atenolol mole-
cules to locate themselves inside the lipid bilayer membrane (withdifferent extents, as reported byHan and Lee [27]), but the PEGylated
amlodipine molecules becomemore hydrophilic than their ordinary
forms (free energy analysis justiﬁes these results in Fig. 8).
2. PEGylation increases the diffusion coefﬁcients of the simulated
drugs, but other factors such as the hydrophilic nature of the drugs
and the energy barrier in the simulation system, as well as the
dislocations of lipid molecules should be considered to justify the
diffusion process.
3. PEGylation makes atenolol and lisinopril take up an orientation to-
ward the bilayer which facilitates the diffusion into the membrane,
but PEGylated amlodipine molecules have the same orientations as
the ordinary forms of this drug.
4. PEGylation increases the electrostatic potential of atenolol and
lisinopril which can be due to their instability in the transition region
between hydrophilic and hydrophobic states, but the electrostatic
potential of amlodipine molecules is less than that of the ordinary
form of the drug due to the presence of more stable level of hydro-
philicity after PEGylation which is the same behavior as reported
for the stability of PEGylated insulin [25].
5. Type of the spacermolecule (amide or ester bonded) does not have a
structural effect on the drug's behavior; however, the ester bonded
form (for all the three drugs) increases the diffusion coefﬁcient and
the amide bonded form of PEGylated lisinopril has higher effect on
the DMPC orders.
The results indicated that, decreasing the hydrophilic behavior of the
drugs increases their tendency to diffuse into the lipid bilayer mem-
brane for the systems containing lisinopril and atenolol molecules, but
an inverse effect is observed for the systems containing amlodipine
molecules.
In addition, in future research we intend to study the drug dosage,
novel multiarm PEGs, anti-hypertensive drug mixtures, the effective-
ness of the conjugated drugs, lipid bilayer membrane with a receptor
and the other types of the anti-hypertensive drugs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2015.04.016.Transparency document
The Transparency document associated with this article can be
found, in the online version.
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